ANPEP and cholangiocarcinoma: More recent publications have identified CD13 as a CSC-specific membrane marker, including for hepatocellular carcinoma (HCC), and cholangiocarcinoma [20,21]; it exhibits preferential expression on cells of the side population (SP), which are characterized by extremely high chemoresistance and tumorigenicity in transplantation models.